Analyst RecommendationAnalyst recommendation for Viridian is 'OUTPERFORM', suggesting confidence in the company's performance.
Pipeline ProgressViridian recently completed enrollment of the REVEAL program, which is evaluating VRDN-003 in both active and chronic Thyroid Eye Disease.
Product DesignationVeligrotug has been granted Breakthrough Therapy Designation, indicating its potential as a valuable treatment option.
Therapy EfficacyVRDN's Veligrotug demonstrated a significantly higher proptosis response rate compared to Roche's Satralizumab, positioning it as a more effective treatment for TED.